Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
Luca MonzoJoão Pedro FerreiraJohn G F ClelandPierpaolo PellicoriBeatrice MariottoniMark R HazebroekTim J CollierJoe J CuthbertBurkert PieskeJohannes PetutschniggFozia Z AhmedNicolas GirerdAndrew L ClarkFranco CosmiJan A StaessenStephane HeymansPatrick RossignolFaiez ZannadPublished in: ESC heart failure (2022)
In people at risk for developing HF and with relatively normal renal function, spironolactone reduced the risk of hypokalaemia and, at the doses used, was not associated with the occurrence of clinically meaningful hyperkalaemia.